{"product_id":"organon-swot-analysis","title":"Organon SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOrganon’s focused women’s health portfolio, strong R\u0026amp;D pipeline, and global commercial footprint position it well for steady growth, but patent expiries, regulatory hurdles, and competitive generics present clear risks; strategic partnerships and diversified product launches are key opportunities. Discover the full SWOT analysis for a detailed, editable report and Excel tools to support investment, strategy, and pitch-ready planning—available instantly after purchase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership in Long-Acting Reversible Contraception\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon leads the global contraception market with Nexplanon as the gold standard in long-acting reversible contraception, holding roughly 40% share of implant prescriptions in key markets by 2025.\u003c\/p\u003e\n\u003cp\u003eThe Nexplanon franchise delivers high margins—estimated gross margin ~72% in 2024—and provides a durable revenue base, contributing about $1.1 billion of Organon’s 2025 product sales.\u003c\/p\u003e\n\u003cp\u003eOrganon expanded clinical adoption across Europe, Latin America, and APAC by end-2025, using a specialized sales force that increased implant unit growth ~8% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Portfolio of Established Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon manages 60+ marketed medicines across cardiovascular, respiratory and non-opioid pain, with legacy brands delivering predictable cash—product sales drove $2.5B in FY2024 revenue (U.S. net sales ~ $1.6B), funding R\u0026amp;D (~$520M in 2024) and acquisitions; this breadth lowers single-product risk and buffers against country-specific downturns, so a failure in one therapy has limited impact on consolidated cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Global Commercial Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon sells products in over 140 markets, giving it scale across the US, Europe, and fast-growing regions like LATAM and SEA; international sales were ~46% of 2024 revenue ($3.2B of $7.0B), so global reach materially diversifies cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Free Cash Flow Generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cporganon efficient model generated about billion in free cash flow fiscal funding debt service and million shareholder returns while keeping leverage near net by mid-2025.\u003e\n\u003cpthis liquidity lets organon fund m and r internally partner strategically with disciplined allocation through late balancing organic investment external deals.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 FCF ≈ $1.1B\u003c\/li\u003e\n\u003cli\u003eShareholder returns ≈ $350M (2024)\u003c\/li\u003e\n\u003cli\u003eLeverage ~2.5x net debt\/EBITDA (mid-2025)\u003c\/li\u003e\n\u003cli\u003eEnables internal funding for M\u0026amp;A and R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/porganon\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnique Pure-Play Focus on Womens Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganon’s pure-play focus on women’s health gives it a clear brand edge and deep clinical know-how, driving 2024 revenue of $3.0B in women’s health and a 5-year CAGR of ~7% (2019–2024).\u003c\/p\u003e\n\u003cp\u003eThat specialization strengthens ties with OB‑GYNs, midwives, and advocacy groups, improving trial recruitment and product uptake versus broad-based peers.\u003c\/p\u003e\n\u003cp\u003eThe niche creates a durable moat—competitors with diversified portfolios face higher cost and time to match Organon’s channel access and clinical depth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 women’s health revenue: $3.0B\u003c\/li\u003e\n\u003cli\u003e5‑yr CAGR (2019–2024): ~7%\u003c\/li\u003e\n\u003cli\u003eStronger provider \u0026amp; advocacy relationships\u003c\/li\u003e\n\u003cli\u003eHard-to-replicate market moat vs diversified pharma\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon: Nexplanon-led margins, $1.1B FCF and global women’s health growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon’s strengths: Nexplanon dominance (~40% implant share; ~$1.1B sales 2025) drives high gross margin (~72% 2024); diversified 60+ portfolio and global reach (sales in 140+ markets; international ~46% of 2024 revenue $3.2B of $7.0B) produce ~$1.1B FCF (2024) and leverage ~2.5x net debt\/EBITDA (mid‑2025), while women’s health focus yielded $3.0B revenue (2024; 5‑yr CAGR ~7%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNexplanon sales (2025)\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (2024)\u003c\/td\u003e\n\u003ctd\u003e~72%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWomen’s health rev (2024)\u003c\/td\u003e\n\u003ctd\u003e$3.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl share (2024)\u003c\/td\u003e\n\u003ctd\u003e~46%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeverage (mid‑2025)\u003c\/td\u003e\n\u003ctd\u003e~2.5x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Organon, highlighting its core strengths, operational weaknesses, market opportunities, and external threats to inform strategic and investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a focused Organon SWOT snapshot for rapid strategic alignment and clear stakeholder communication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Long-Term Debt Burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon inherited about $9.4 billion of long-term debt from Merck at the 2021 spin-off and still carried roughly $6.8 billion net debt by YE 2025, constraining free cash flow for R\u0026amp;D and M\u0026amp;A.\u003c\/p\u003e\n\u003cp\u003eAnnual interest expense near $420 million in 2024 reduced discretionary capital, and a 60% net-debt-to-EBITDA ratio in 2025 raises sensitivity to rate rises and tighter credit conditions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue Concentration in Key Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite a broad portfolio, Organon reported that in 2024 Nexplanon and a handful of women’s health products accounted for roughly 40% of net sales, concentrating revenue risk. A regulatory recall or a generic\/competitive launch in that segment could shave material EBITDA—potentially several hundred million dollars given 2024 adjusted EBITDA of about $2.1 billion. Investors flag this dependency versus peers with more diversified revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Mature Product Attrition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA large share of Organon’s Established Brands are mature medicines facing ongoing price erosion and generics; Established Brands revenue fell 9% to $2.1B in FY2024, reflecting that pressure. As patents expire and low-cost entrants arrive, sustaining historical margins (EBIT margin for Established Brands was ~18% in 2024) gets harder. Organon must innovate or buy new assets to offset attrition; R\u0026amp;D spend was $812M in 2024 to support that pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Third-Party Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrganon depends on a complex network of third-party suppliers and contract manufacturers for finished drugs and active pharmaceutical ingredients, exposing it to quality-control, regulatory and supply disruptions outside its direct control.\u003c\/p\u003e\n\u003cp\u003eIn 2024 roughly 30% of Organon’s product volume came from external manufacturers; a major partner failure could cause shortages and revenue loss—Organon reported $3.5bn sales in women’s health in 2024, so even small disruptions matter.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30% external manufacturing (2024)\u003c\/li\u003e\n\u003cli\u003eQuality\/regulatory risk → product shortages\u003c\/li\u003e\n\u003cli\u003eSupply\/cost volatility not fully controllable\u003c\/li\u003e\n\u003cli\u003ePotential hit to $3.5bn segment revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Early-Stage Internal Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrganon lacks a deep early-stage R\u0026amp;D engine versus big pharmas, leaning on late-stage buys and branded legacy products; in 2024 R\u0026amp;D spend was about $450m versus peers spending $2–4bn, showing dependence on external deals.\u003c\/p\u003e\n\u003cp\u003eThis forces steady BD and licensing to replace maturing revenues—acquisitions cost more and 2023–24 deal premiums rose ~25%, raising acquisition costs and bidding competition.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 R\u0026amp;D $450m; peers $2–4bn\u003c\/li\u003e\n\u003cli\u003eDeal premiums up ~25% (2023–24)\u003c\/li\u003e\n\u003cli\u003eHigher per‑asset cost, intense BD competition\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon: High debt, concentrated women's‑health sales and below‑peer R\u0026amp;D constrain upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon carried roughly $6.8B net debt at YE 2025, limiting FCF for R\u0026amp;D\/M\u0026amp;A; 2024 interest expense was ~$420M and net‑debt\/EBITDA ~60% (2025), raising rate sensitivity. Nexplanon and a few women’s health products drove ~40% of 2024 sales, concentrating revenue risk against generics\/recalls. Established Brands declined 9% to $2.1B in FY2024; R\u0026amp;D was ~$450M (2024), well below big‑pharma peers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (YE 2025)\u003c\/td\u003e\n\u003ctd\u003e$6.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest expense (2024)\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet‑debt\/EBITDA (2025)\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNexplanon share of sales (2024)\u003c\/td\u003e\n\u003ctd\u003epart of ~40% women’s health\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstablished Brands (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$2.1B, -9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003e$450M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eOrganon SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752715399545,"sku":"organon-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/organon-swot-analysis.png?v=1772244251","url":"https:\/\/growthsharematrix.com\/products\/organon-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}